CN108514582A - A kind of component compatibility Chinese medicine of prevention Alzheimer disease - Google Patents
A kind of component compatibility Chinese medicine of prevention Alzheimer disease Download PDFInfo
- Publication number
- CN108514582A CN108514582A CN201810762110.XA CN201810762110A CN108514582A CN 108514582 A CN108514582 A CN 108514582A CN 201810762110 A CN201810762110 A CN 201810762110A CN 108514582 A CN108514582 A CN 108514582A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- rhizoma chuanxiong
- coptis
- extract
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of component compatibility Chinese medicine of prevention Alzheimer disease, the extract of traditional Chinese medicine effective ingredient, raw material consists of the following compositions：Ginseng or general ginsenoside；The coptis or coptis chinensis total alkaloid；And Rhizoma Chuanxiong or Rhizoma Chuanxiong alcohol extract.Compared to Chinese medicine original side (prepared fleece flower root, ginseng, grass-leaved sweetflag, the coptis and Rhizoma Chuanxiong), the new compatibility of traditional Chinese medicinal components in terms of Animal Behavior Science and the index of pathological change be better than original side compatibility, in terms of inhibiting level of inflammation with the effect having the same of original side.Reduce the toxic effect and drug dose of original side simultaneously, and its active ingredient including ginsenoside, jamaicin and ligustrazine is clear and can play pharmacological action by blood-brain barrier, traditional Chinese medicinal components compatibility, meet Chinese medicine traditional theory, effective substance is clear, the characteristics of embodying modern Chinese herbal medicine preparation is the ideal medicament for preventing senile dementia.
Description
Technical field
The present invention relates to traditional Chinese medicine research technical fields, and in particular to it is a kind of prevention Alzheimer disease component compatibility in
Medicine.
Background technology
Alzheimer disease (Alzheimer's disease, AD) is also known as senile dementia, is to be only second to heart disease, cancer
After disease, palsy, it is exactly learning and memory function to lead to the fourth-largest killer of the elderly's death, most significant behavioural characteristic
Progressive fails.As China steps into aging society, AD numbers of patients are in continuous growth trend, in Chinese over-65s
Old man in AD illness rates be 3.21%, more than 7,000,000 AD patients occupy first of countries in the world.The course of disease of AD is long, complication
It is more, it needs to look after for a long time, not only influences the life quality of patient, return family, individual brings serious society and economic problems.
Research accordingly, with respect to AD pathogenesis and prevention has become this century China's gerontology field and society merits special attention
And one of problem urgently to be resolved hurrily.
Senile dementia is Chronic Progressive disease, and its state of an illness is irreversible with advancing age, at present about AD
The interpretation of the cause, onset and process of an illness there are many theory, but exact interpretation of the cause, onset and process of an illness mechanism is still not clear.Show that shrinking of brain tissues, cerebral cortex go out on pathology
Phenomena such as existing senile plaque.Research finds that senile plaque is caused by the deposition of amyloid beta, but amyloid beta whether be
It is being showed after the immediate cause of this disease or illness as a result, coming to a conclusion currently not yet.Therefore, there are no needles so far
To the effective therapies of AD, the key point for controlling disease is to accomplish early discovery, early intervention.2017 dementia of PLOS medicine is special
The associate editor Bruce Miller professors of periodical and Carol professors Brayne point out jointly, and it is this to treat Alzheimer disease at present
Complex disease, which is absorbed in single creature target spot, may sow the seed of clinical failure.Therefore, countries in the world medical field is all
Actively research and develop the drug and method of effective integrated control AD.
AD is belonged to the scopes such as " forgetful ", " dementia " by Traditional Chinese Medicine, belongs to Primary Asthenia-Secondary Sthenia Syndrome, and deficiency of kidney-QI is it, phlegm
Turbid, blood stasis, poison is evil mutually becomes its mark, and asthenia in origin and asthenia in superficiality interacts, and interaction forms void, the stasis of blood, turbid, malicious vicious circle have to suffer from
Evil network.Promoting blood circulation and removing blood stasis clinically mostly with qi and activate blood circulation, the methods of promoting blood circulation and detoxication treats AD, achieves preferable curative effect.
Based on this theoretical foundation, applicant has developed a kind of Chinese medicine compound prescription (China that can effectively prevent Alzheimer disease
Patent publication No. CN102078460A), including prepared fleece flower root, ginseng, grass-leaved sweetflag, the coptis and Rhizoma Chuanxiong, the fleece-flower root is monarch drug in a prescription in side,
Filling liver kidney, replenishing essence marrow；Ginseng is ministerial drug, QI invigorating qi-restoratives, and the fleece-flower root is helped to mend the deficient of internal organs, and assistant is to be that grass-leaved sweetflag, the coptisization are turbid
Have one's ideas straightened out, solve the poison of gods, Rhizoma Chuanxiong is to make medicine, promoting blood circulation and removing blood stasis and carry medicine uplink in brain.All medicine phases 5 play and tonify Qi of the kidney, invigorate blood circulation altogether
The effect of removing toxic substances.
Although above-mentioned prescription function is notable, constituent is more, and potential adverse reaction and the expected property of taboo are relatively low.Most
Closely it has been reported that the fleece-flower root has hepatotoxicity wind agitation, human liver is had damage, it is therefore desirable to examine closely again each in compatibility of drugs
The selection of ingredient and dosage.
Invention content
The purpose of the present invention is on the basis of original Chinese medicine preparation, providing a kind of drug effect significant Chinese medicinal compound extract,
The new formula Chinese medicine or Chinese medicinal compound extract that its formula constituent is reduced.
The present invention surrounds the pathogenesis of AD " the empty turbid poison of the stasis of blood-", finds to select ginseng, the coptis and Rhizoma Chuanxiong compatibility, also can
Achieve the effect that treat AD, in the pharmaceutical composition, contains ginsenoside, chuanxingol, ligustrazine, the jamaicin being easily absorbed by the body
Etc. active ingredients, study of pharmacy also indicate that its active ingredient ginsenoside, jamaicin and ligustrazine can by blood-brain barrier, send out
Waving it has improvement brain tissue pathology change and delaying aging, enhances body cognitive ability, improves the work of learning and memory ability
With.Drug is made of natural plants completely, is free of hormone, does not also add other synthetics such as pigment, right after continuous use
Human body has no toxic side effect.
The extract general ginsenoside of ginseng, the extract coptis chinensis total alkaloid of the coptis and Rhizoma Chuanxiong alcohol extract, Ke Yifen
Corresponding crude drug is not replaced.Wherein, general ginsenoside is the dry of Araliaceae ginseng Panax ginseng C.A.Mey.
Dry or the processed manufactured total saposins of rhizome, can select commercial goods, or voluntarily extract.
Coptis chinensis total alkaloid is that the dry rhizome of ranunculaceae plant coptis Coptis chinensis Franch. is processed
Manufactured total alkaloid can select commercial goods, or voluntarily extract.
Rhizoma Chuanxiong alcohol extract is the dry rhizome of samphire Rhizoma Chuanxiong Ligusticum chuanxiong Hort. through adding
Alcohol extracting thing made of work can select commercial goods, or voluntarily extract.
Preferably, above-mentioned Chinese medicine, is counted in parts by weight, and each raw material dosage is：
1 part of 9 parts of ginseng or general ginsenoside；
5 parts of 5 parts of the coptis or coptis chinensis total alkaloid；
And 12 parts of 6 parts of Rhizoma Chuanxiong or Rhizoma Chuanxiong alcohol extract.
Granule, capsule, soft capsule, electuary, pill or soft extract can be made in above-mentioned Chinese medicine.The letter of its manufacture craft
It is single, it is at low cost, it is made completely of natural plants, is free of hormone, does not also add other synthetics such as pigment, be used continuously
Afterwards, it has no toxic and side effect to human body.
Preferably, the preparation method of above-mentioned Chinese medicine, the general ginsenoside is as follows：
Ginseng crude drug is taken, is cleaned, segment adds water to cook secondary, 2 hours first times, second 1.5 hours, decocting liquid filtration,
Merging filtrate, by D101 type large pore resin absorption columns, water elution collects 60% ethyl alcohol to colourless, then with 60% ethanol elution
Eluent, filtrate be concentrated into relative density be 1.06~1.08 (80 DEG C) clear cream, 100 DEG C of dryings, 100 mesh crush to get at
Product.
Preferably, the preparation method of above-mentioned Chinese medicine, the coptis chinensis total alkaloid is as follows：
Rhizoma Coptidis is taken, is cleaned, 12mm is crushed to, dilute sulfuric acid heat-insulation soaking is added to extract, limewash and sodium chloride is added to alkalize
Crystallization, filtering are dissolved in water and adjust pH value, and hydrochloric acid acidification filtering is added, with purifying water washing, 75 DEG C~80 DEG C dryings, and 80
Mesh crushes to get finished product.
Preferably, the preparation method of above-mentioned Chinese medicine, the Rhizoma Chuanxiong alcohol extract is as follows：
Ligusticum chuanxiong Hort is taken, is cleaned, medicine materical crude slice is cut, 70% ethyl alcohol is added to extract 2 times, 10 times of 70% ethyl alcohol of amount extract 2h for the first time,
Second of 8 times of 70% ethyl alcohol of amount extracts 2h, merges extracting solution, and recycling ethyl alcohol is dried under reduced pressure to no alcohol taste, crushes to get Rhizoma Chuanxiong
Alcohol extracting thing.
In the present invention, the percentage composition of ethyl alcohol is the percentage composition that ethyl alcohol accounts for ethanol water total volume.
Compared with prior art, the present invention has the advantages that：
Compared to Chinese medicine original side (prepared fleece flower root, ginseng, grass-leaved sweetflag, the coptis and Rhizoma Chuanxiong), the new compatibility of traditional Chinese medicinal components is in animal
In terms of behaviouristics and the index of pathological change is better than original side compatibility, in terms of inhibiting level of inflammation with original side's work having the same
With.Reduce the toxic effect and drug dose of original side simultaneously, and it is including ginsenoside, jamaicin and ligustrazine etc.
Active ingredient can play pharmacological action by blood-brain barrier, clear with component compatibility, meet Chinese medicine traditional theory, and and existing
The ideal medicament of prevention senile dementia is combined for preparation.
Description of the drawings
Fig. 1 be Chinese medicine of the present invention newly side compatibility group to CA 1 of Hippocampus pathological change (HE × 40) testing result, wherein
A：Blank group, B：Model group, C：Doneppezil Hydrochloride group, D：Chinese medicine original side group, E：The new square group of Chinese medicine.
Specific implementation mode
It is prepared by 1.0 drug ingedients
General ginsenoside：Extracting method is as follows, takes ginseng crude drug, cleans, segment, add water to cook it is secondary, it is 2 small for the first time
When, second 1.5 hours, decocting liquid filtration, merging filtrate, by D101 type large pore resin absorption columns, water elution was to colourless, then uses
60% ethanol elution collects 60% ethanol eluate, and filtrate is concentrated into the clear cream that relative density is 1.06~1.08 (80 DEG C),
100 DEG C of dryings, 100 mesh crush to get finished product, general ginsenoside>80% storage, yield is 4%.
Coptis chinensis total alkaloid：Extracting method is as follows, takes Rhizoma Coptidis, cleans, and is crushed to 12mm, adds dilute sulfuric acid heat-insulation soaking
Extraction adds limewash and sodium chloride to alkalize and crystallizes, and filtering is dissolved in water and adjusts pH value, hydrochloric acid acidification filtering is added, with purifying
Water washing, 75 DEG C~80 DEG C dryings, 80 mesh crush to get finished product, coptis chinensis total alkaloid>12% storage, yield is 10%.
Rhizoma Chuanxiong alcohol extract：By China TCM Academy of Sciences Xiyuan Hospital prepared by Drug Manufacturing Room, and extracting method is as follows, takes Rhizoma Chuanxiong former
Material, cleans, and 70% ethyl alcohol is added to extract 2 times, and 10 times of 70% ethyl alcohol of amount extract 2h, second of 8 times of amount 70% ethyl alcohol extraction for the first time
2h, merge extracting solution, recycling ethyl alcohol to no alcohol taste, be dried under reduced pressure, crushing to get.
1.1 experimental drug
Chinese medicine original side compatibility group (Chinese medicine original side group)：12 parts of prepared fleece flower root, 9 parts of ginseng, 10 parts of grass-leaved sweetflag, 6 parts of Rhizoma Chuanxiong are yellow
Even 5 parts；
The new square compatibility group (the new square group of Chinese medicine, in embodiment also referred to as Fuzheng Quxie Decoction) of Chinese medicine：1 part of general ginsenoside, it is yellow
Even 5 parts of total alkaloid, 12 parts of Rhizoma Chuanxiong alcohol extract (are equivalent to 9 parts of ginseng, 5 parts of the coptis, 6 parts of Rhizoma Chuanxiong)；
Positive control drug：Doneppezil Hydrochloride.
1.2 experimental animals, grouping and administration
Using naturally-aged rat model, using Morris determined with Morris water, with Younger group rat average escape latency
95% and 99% range of normal value upper limit value is boundary, and senile rat is divided into learning and memory impairment group and normal group of learning and memory,
It is divided into 5 groups, every group 10 according to the method for stratified random in conjunction with weight.Select the normal senile rat conduct pair of cognitive function
According to.It is shown in Table 1.
1 traditional Chinese medicinal components of table are prepared and animal packet
After gavage 2 months, each group rat is detected animal behavioral study.Cranium is opened after anesthesia and takes brain, detaches cerebral cortex
And hippocampus, in -80 DEG C of preservations, experimentation meets《Beijing's Laboratory Animal Welfare Ethic review guide》Requirement.
1.3 Indexs measure
1.3.1 rat behavior is observed
Morris water maze laboratories：Orientation navigation experiment is carried out to test with space exploration.Orientation navigation experiment statistic is
Escape latency seeks number；The space exploration experiment statistics rat original platform quadrant swim time accounts for total swimming time percentage,
Across original platform number.
1.3.2 Rat hippocampus Pathomorphology feature
Brain tissue is taken to be fixed in 10% neutral formalin liquid, paraffin section.HE is dyed and congo red staining, observes hippocampal tissue
The areas CA1 morphological change and the variation of the deposition of amyloid protein.
1.3.3 the level of rat blood serum cholinergic, amyloid beta and inflammatory factor
Take rat blood serum, using enzyme-linked immunization detect serum in acetylcholine (Ach), amyloid beta (β-AP), in vain
Interleukin -6 (IL-6), proleulzin (IL-2), interleukin-10 (IL-10) and levels of tnf-alpha (TNF-α) content.
1.4 experimental result
1.4.1 to the influence of rat hippocampus Pathomorphology
Old blank group CA 1 of Hippocampus cell level has no reduction, and it is irregular that arrangement is slight, and cell arrangement is close,
Neuronal cell has no denaturation, is dispersed in microglia.Model group cell level significantly reduces, disorganized, loose, neuron
Cell degeneration, nuclear hyperchromatism have a large amount of microglia hyperplasia.Compared with model group, donepezil group cell level increases, arrangement
Relatively regular, neuronal cell is denaturalized unobvious, is dispersed in microglia；Newly just group cell level increases for Chinese medicine original side group, Chinese medicine,
It arranges close, regular, has no the denaturation of apparent neuronal cell, be dispersed in microglia hyperplasia, and newly just group improves more Chinese medicine
Obviously, the result is shown in Figure 1.
1.4.2 to the influence of treated rats in Morris water maze performance
Space exploration is tested：Compared with blank control group, the escape latency of model group rats is obviously prolonged, and difference has system
Meter learns meaning (P ＜ 0.01)；Compared with model group, the escape latency that Chinese medicine original side group, Chinese medicine are newly just organized is obviously shortened, poor
Different statistically significant (P ＜ 0.01), and the escape latency that Chinese medicine is newly just organized is substantially better than Chinese medicine original side group, the results are shown in Table 2.
The influence preclinical on senile rat of 2 Fuzheng Quxie Decoction of table (min,)
Note：Compared with blank control group,##p<0.01；Compared with model group, * p<0.05, * * p<0.01；
Compared with Chinese medicine original side group,▲p<0.05,▲▲p<0.01。
Orientation navigation experiment：Compared with blank control group, model group original platform quadrant activity distance wears platform number than reducing
It reduces, statistically significant (the P ＜ 0.01 of difference；P ＜ 0.05)；Compared with model group, Chinese medicine original side group, Chinese medicine are newly just organized
For rat original platform quadrant activity distance than increasing, difference is statistically significant (P ＜ 0.05)；Compared with model group, Chinese medicine original side
It rat original platform quadrant activity time that group, Chinese medicine are newly just organized and wears platform number and has increase trend, but difference is without statistics
Meaning (P>0.05) 3, be the results are shown in Table.
3 Fuzheng Quxie Decoction of table to senile rat space exploration ability influence ()
Note：Compared with blank control group,#p<0.05,##p<0.01；Compared with model group,**p<0.01。
1.4.3 to the influence of acetylcholine, β-AP contents in rat blood serum
Compared with blank group rat, the content of acetylcholine significantly reduces in model group rats serum, and β-AP contents are apparent
It increases, two groups of differences are statistically significant (P ＜ 0.01, P ＜ 0.05)；Compared with model group rats, donepezil group rat
The content of acetylcholine significantly increases in serum, and β-AP contents have reduction trend (P ＜ 0.01, P>0.05)；Chinese medicine original side group, in
The content that medicine newly just organizes acetylcholine in rat blood serum significantly increases, and β-AP contents significantly reduce, and difference has statistics meaning
Adopted (P ＜ 0.05, P ＜ 0.01), the results are shown in Table 4.
4 Fuzheng Quxie Decoction of table to acetylcholine in rat blood serum, β-AP contents influence ()
Note:Compared with blank control group,#p<0.05,##p<0.01；Compared with model group,*p<0.05,**p<0.01。
1.4.4 influence of the Fuzheng Quxie Decoction to inflammation-related factor content in rat blood serum
Compared with blank group rat, TNF α in model group rats serum, IL-6 content significantly increase, and difference has
Statistical significance (P ＜ 0.01, P ＜ 0.01)；Compared with model group rats, the content of TNF α is aobvious in donepezil group rat blood serum
Writing reduces, and IL-6 contents have reduction trend (P ＜ 0.05, P>0.05)；Chinese medicine original side group, Chinese medicine newly just organize TNF in rat blood serum
The content of α, IL-6 significantly reduce, and difference is statistically significant (P ＜ 0.05, P ＜ 0.01).
Compared with blank control group rat, the content of IL-2 significantly increases in model group rats serum, and difference has system
Meter learns meaning (P ＜ 0.01)；Compared with model group rats, IL-2 contents have reduction trend in donepezil group rat blood serum, but
No significant difference (P>0.05)；The content that Chinese medicine original side group, Chinese medicine newly just organize IL-2 in rat blood serum significantly reduces,
Difference is statistically significant (P ＜ 0.05, P ＜ 0.01).Compared with blank control group rat, IL-10 in model group rats serum
Content have raising trend, but no significant difference (P>0.05)；Compared with model group rats, donepezil group, Chinese medicine
The content that original side's group, Chinese medicine newly just organize IL-10 in rat blood serum significantly increases, statistically significant (P ＜ 0.05, the P ＜ of difference
0.01) 5, be the results are shown in Table.
5 Fuzheng Quxie Decoction of table to Inflammatory Factors Contents in rat blood serum influence ()
Note：Compared with the control group,##p<0.01；Compared with model group,*p<0.05,**p<0.01。
1.5 conclusion
Chinese medicine think the cause of disease of AD be due to kidney essence deficiency, marrow disappear brain subtract, refreshing machine appraxia.The interpretation of the cause, onset and process of an illness is asthenia in origin and asthenia in superficiality, this void
Refer generally to damage of kidney-essence, insufficiency of vital energy and blood is marked actually turbid phlegm blocking the clear orifices, stopped in ecchymosis.Prevention of the Chinese medicine for senile dementia, early stage
Just there is ancient books and records record in B.C. beginning, diagnosis and treatment, integrally-regulated principle are focused in prevention, and make since the poison of Chinese medicine is secondary
With relatively small, have the function of multicomponent, multiple target point, is the ideal medicament for preventing senile dementia.Chinese medicine compound prescription first wife 5
By prepared fleece flower root, ginseng, grass-leaved sweetflag, Rhizoma Chuanxiong and coptis composition, the new compatibility of Chinese medicine by ginseng (or general ginsenoside), the coptis (or
Coptis chinensis total alkaloid), Rhizoma Chuanxiong (or Rhizoma Chuanxiong alcohol extract) compatibility composition, the two can be effectively improved the knowledge of senile dementia rat model space
Other ability and learning and memory function inhibit the deterioration of rat cerebral tissue's hippocampus pathomorphism, improve the cellular morphology of brain tissue.With
Relatively, the new compatibility of traditional Chinese medicinal components is in terms of Animal Behavior Science and the index of pathological change is better than original side's compatibility, is pressing down for Chinese medicine original side
Level of inflammation aspect processed and the effect having the same of original side.Reduce the toxic effect and drug dose of original side simultaneously, and it contains
Some part active ingredient ginsenosides, jamaicin and ligustrazine can play pharmacological action by blood-brain barrier, have component
Compatibility is clear, meets Chinese medicine traditional theory, and the ideal medicament of prevention senile dementia is combined with Modern preparations.
Specific case used herein elaborates inventive concept, the explanation of above example is only intended to
Help understands core of the invention thought.It should be pointed out that for those skilled in the art, not departing from this
Under the premise of inventive concept, any obvious modification, equivalent replacement or the other improvements made should be included in the present invention
Protection domain within.
Claims (6)
1. a kind of component compatibility Chinese medicine of prevention Alzheimer disease, which is characterized in that raw material consists of the following compositions：
Ginseng or general ginsenoside；
The coptis or coptis chinensis total alkaloid；
And Rhizoma Chuanxiong or Rhizoma Chuanxiong alcohol extract.
2. Chinese medicine according to claim 1, which is characterized in that count in parts by weight, each raw material dosage is：
1 part of 9 parts of ginseng or general ginsenoside；
5 parts of 5 parts of the coptis or coptis chinensis total alkaloid；And
12 parts of 6 parts of Rhizoma Chuanxiong or Rhizoma Chuanxiong alcohol extract.
3. Chinese medicine according to claim 1 or 2, which is characterized in that dosage form is granule, capsule, soft capsule, electuary, drop
Pill or soft extract.
4. Chinese medicine according to claim 1 or 2, which is characterized in that the preparation method of the general ginsenoside is as follows：
Ginseng crude drug is taken, is cleaned, segment adds water to cook secondary, 2 hours first times, second 1.5 hours, and decocting liquid filtration merges
Filtrate, by D101 type large pore resin absorption columns, water elution collects 60% ethanol elution to colourless, then with 60% ethanol elution
Liquid, filtrate are concentrated into the clear cream that relative density is 1.06~1.08 (80 DEG C), 100 DEG C of dryings, and 100 mesh crush to get finished product.
5. Chinese medicine according to claim 1 or 2, which is characterized in that the preparation method of the coptis chinensis total alkaloid is as follows：
Rhizoma Coptidis is taken, is cleaned, 12mm is crushed to, dilute sulfuric acid heat-insulation soaking is added to extract, adds limewash and sodium chloride to alkalize and crystallizes,
Filtering is dissolved in water and adjusts pH value, and hydrochloric acid acidification filtering is added, with purifying water washing, 75 DEG C~80 DEG C dryings, 80 mesh powder
It is broken to get finished product.
6. Chinese medicine according to claim 1 or 2, which is characterized in that the preparation method of the Rhizoma Chuanxiong alcohol extract is as follows：
Take Ligusticum chuanxiong Hort, clean, cut medicine materical crude slice, add 70% ethyl alcohol extract 2 times, for the first time 10 times amount 70% ethyl alcohol extract 2h, second
70% ethyl alcohol of secondary 8 times of amounts extracts 2h, merges extracting solution, and recycling ethyl alcohol is dried under reduced pressure to no alcohol taste, crushes to get Rhizoma Chuanxiong alcohol extracting
Take object.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810762110.XA CN108514582A (en) | 2018-07-12 | 2018-07-12 | A kind of component compatibility Chinese medicine of prevention Alzheimer disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810762110.XA CN108514582A (en) | 2018-07-12 | 2018-07-12 | A kind of component compatibility Chinese medicine of prevention Alzheimer disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108514582A true CN108514582A (en) | 2018-09-11 |
Family
ID=63428638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810762110.XA Pending CN108514582A (en) | 2018-07-12 | 2018-07-12 | A kind of component compatibility Chinese medicine of prevention Alzheimer disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108514582A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109498751A (en) * | 2019-01-16 | 2019-03-22 | 北京化工大学 | A kind of Chinese medicine that preventing and treating Alzheimer disease-desert cistanche ginseng lotus rhizome of chuanxiong wisdom side and preparation method thereof |
| CN109512951A (en) * | 2019-01-18 | 2019-03-26 | 北京化工大学 | A kind of Chinese medicine that preventing and treating Alzheimer disease-desert cistanche joins sweet rhizome of chuanxiong Yizhi Decoction and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102078460A (en) * | 2011-01-14 | 2011-06-01 | 中国中医科学院西苑医院 | Traditional Chinese medicine for preventing and treating Alzheimer disease and preparation method thereof |
-
2018
- 2018-07-12 CN CN201810762110.XA patent/CN108514582A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102078460A (en) * | 2011-01-14 | 2011-06-01 | 中国中医科学院西苑医院 | Traditional Chinese medicine for preventing and treating Alzheimer disease and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| HEND M. HUSSIEN: "Neuroprotective effect of berberine against environmental heavy metals-induced neurotoxicity and Alzheimer"s-like disease in rats", 《FOOD AND CHEMICAL TOXICOLOGY》 * |
| 史作清: "《吸附分离树脂在医药工业中的应用》", 30 September 2008, 北京：化学工业出版社 * |
| 涂瑶生: "黄连生物碱提取及纯化工艺研究", 《中药新药与临床药理》 * |
| 贾星星: "扶正祛邪方对SAMP8小鼠学习记忆及NMDAR/PP2A/tau通路蛋白表达的影响", 《中国优秀硕士学位论文全文数据库 医药卫生科特辑》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109498751A (en) * | 2019-01-16 | 2019-03-22 | 北京化工大学 | A kind of Chinese medicine that preventing and treating Alzheimer disease-desert cistanche ginseng lotus rhizome of chuanxiong wisdom side and preparation method thereof |
| CN109512951A (en) * | 2019-01-18 | 2019-03-26 | 北京化工大学 | A kind of Chinese medicine that preventing and treating Alzheimer disease-desert cistanche joins sweet rhizome of chuanxiong Yizhi Decoction and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105943888B (en) | Traditional Chinese medicine composition for improving memory and mild cognitive impairment and preparation method thereof | |
| CN101869600A (en) | Medicinal composition for treating degenerative change in central nervous system, preparation method and application thereof | |
| CN108514582A (en) | A kind of component compatibility Chinese medicine of prevention Alzheimer disease | |
| CN103566087B (en) | Pharmaceutical composition for treating cognitive disorder and application thereof in preparation of medicine for treating Alzheimer disease | |
| CN111529653A (en) | A Chinese medicinal composition for treating brain atrophy, Alzheimer's disease, hypomnesis, and epilepsy | |
| CN102188520B (en) | Traditional Chinese medicine composition for the treatment of cerebral ischemia and application thereof | |
| CN104840871B (en) | A kind of Chinese medicine for treating alcoholic liver damage | |
| CN101732369B (en) | Novel application of penthorum chinense pursh extract | |
| CN103735761B (en) | A kind of pharmaceutical composition preventing and treating Alzheimer disease and preparation method thereof | |
| CN109925445A (en) | Anoectochilus causes the application in acute liver drug in preparation prevention and/or treatment D-Gal | |
| CN102293847B (en) | Chinese medicinal composition for treating constipation, acne and hyperlipidemia, and preparation method | |
| CN101732585A (en) | Medicinal composition for treating migraine, preparation method and application thereof | |
| CN101274013A (en) | Prescription medicine for curing senile dementia and preparation | |
| CN107375829A (en) | Treat the Chinese medicine composition of Post-apoplectic and its preparation method of preparation | |
| US20230043437A1 (en) | Compound preparation for neuranagenesis, and preparation method therefor and use thereof | |
| CN105998752B (en) | A kind of Chinese medicine composition for the treatment of of vascular dementia | |
| CN105796620A (en) | New applications of radix notoginseng and radix notoginseng extract to preparation of medicines for treating psoriasis | |
| CN107693593B (en) | Traditional Chinese medicine composition for preventing and treating coronary heart disease | |
| CN114533803B (en) | Traditional Chinese medicine composition for preventing senile dementia and preparation method thereof | |
| CN105194352B (en) | A kind of Chinese medicine composition and preparation method thereof improving learning and memory | |
| CN1453029A (en) | Chinese medicine composition for treating senile dementia | |
| CN102526583B (en) | Chinese medicinal composition for treating senile dementia and preparation method and application thereof | |
| CN108096422A (en) | A kind of Chinese medicine composition for treating senile dementia and preparation method thereof | |
| CN109999155B (en) | Traditional Chinese medicine composition for treating Alzheimer disease and preparation method thereof | |
| CN112999317B (en) | Traditional Chinese medicine composition for preventing and treating diabetes and complications thereof, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180911 |
|
| RJ01 | Rejection of invention patent application after publication |